inS3-54A18
目录号 : GC32862
inS3-54A18 is a potent inhibitor of STAT3 with anti-cancer properties.
Cas No.:328998-53-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
inS3-54A18 is a potent inhibitor of STAT3 with anti-cancer properties.
[1] Huang W, et al. Oncogene. 2016 Feb 11;35(6):783-92. doi: 10.1038/onc.2015.215.
Animal experiment: | Briefly, 5×106 A549 cells are injected subcutaneously in the flanks of 5-6-week-old male NOD/SCID mice. When the tumor volume reach about 50.0 mm3, the mice are randomized using online program into two different groups (6/group) with one group treated by formulation vehicle control and the other by A18 at 200 mg/kg with oral dosing 2-3 times a week for 4 weeks. One mouse in each group dies during the study and is eliminated. Tumor volume and body weight of the remaining five mice in each group are measured twice a week without blinding. On the thirty-fifth day after implant, mice are euthanized and the tumor tissues are harvested and weighed. Necropsy is also performed to determine changes in the heart, lungs, kidneys, liver and spleen. |
References: [1]. Huang W, et al. Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo. Oncogene. 2016 Feb 11;35(6):783-92 | |
| Cas No. | 328998-53-4 | SDF | |
| Canonical SMILES | O=C1N(C2=CC=C(O)C=C2)C(C3=CC=CC=C3)=C/C1=C/C4=CC=C(Cl)C=C4 | ||
| 分子式 | C23H16ClNO2 | 分子量 | 373.83 |
| 溶解度 | DMSO : ≥ 150 mg/mL (401.25 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.675 mL | 13.3751 mL | 26.7501 mL |
| 5 mM | 0.535 mL | 2.675 mL | 5.35 mL |
| 10 mM | 0.2675 mL | 1.3375 mL | 2.675 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet